GH-axis research
CJC-1295 No DAC
Gevriesdroogd endocriene signaleringsonderzoekpeptide voor systeembeoordeling
CJC-1295 No DAC is a short-acting GHRH analog studied as a pituitary GH-axis signaling reference.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesAlleen voor laboratoriumonderzoek. Niet voor menselijk of diergeneeskundig gebruik. Niet bedoeld voor het diagnosticeren, behandelen, genezen, verzachten of voorkomen van ziekten.
Afgesloten, koud, droog en beschermd tegen hitteschommelingen bewaren. Bevestig productspecifieke opslag bij aankomst.
Verpakt voor stabiliteit tijdens het transport, met bestelondersteuning beschikbaar voor routes bij warm weer.
Batch-linked certificate support is available through the documentation desk.
Onderzoekscontext
CJC-1295 No DAC onderzoeksprofiel
CJC-1295 No DAC is used as a shorter-acting GHRH analog reference in pituitary GH-axis research. Studies focus on GHRH-receptor activation, stimulated GH release, pulse timing, downstream IGF-1 markers, and comparisons with longer-acting analogs. The “No DAC” designation separates this material from CJC-1295 versions designed with a drug-affinity complex for albumin binding and prolonged exposure. It is generally selected when the experimental design values shorter signaling windows or direct comparison with sermorelin and secretagogue compounds. Nomenclature for modified GRF and CJC-related peptides can vary, so sequence identity, amount, and batch documents are important parts of product selection.
Molecular class
Modified 29-residue GHRH analog
Sequence / composition
A substituted growth-hormone-releasing-hormone 1-29 analog without a Drug Affinity Complex attachment.
Research design note
The absence of DAC is central to the shorter-exposure pharmacology usually compared in GH-axis studies.
Voorgesteld mechanisme
A short-acting GHRH-receptor agonist concept, often associated in commerce with modified GRF(1-29). GHRH receptor activation increases cyclic AMP in pituitary somatotrophs and promotes pulsatile growth-hormone release.
In studies gerapporteerde effecten
- GHRH analog studies report acute increases in GH release and downstream IGF-1-related signaling, depending on analog and exposure.
- Shorter exposure is expected to produce a different release profile from albumin-binding CJC-1295 with DAC.
- The label "CJC-1295 No DAC" is used inconsistently and may not describe the same sequence studied under the original CJC-1295 name.
Veelgebruikte onderzoekseindpunten
Sequence confirmation, GHRH receptor activity, cyclic AMP, GH pulse amplitude and duration, IGF-1, pituitary responsiveness, degradation, and comparison with DAC-modified material.
Bewijs en beperkingen
GHRH biology is established, but direct evidence is weakened by naming and identity ambiguity. Sequence and batch documentation are especially important.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
GH axis
CJC-1295 with DAC
CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.
- Vorm
- Gevriesdroogd poeder
- Hoeveelheid
- 5 mg
Prijsklasse: 49.99 $ tot 212.99 $ Opties selecteren Dit product heeft meerdere variaties. Deze optie kan gekozen worden op de productpagina